IMed Consultancy explores the pros and cons of the regulatory scenario in key international markets within a changing regulatory environment

IMed Consultancy, a rising regulatory and compliance consultancy provider with over 50 years of experience supporting UK and international medical device and invitro device manufacturers launch and maintain their products on global markets, presents a guide to market entry looking at the EU, the UK and the USA. The whitepaper, available here: https://imedconsultancy.com, looks at these three major markets for medical devices, highlighting some key considerations relating to entering each of these geographies “first” to help manufacturers make informed decisions.

In today’s rapidly evolving landscape of healthcare and technology, navigating the realm of regulatory compliance for medical devices has become an increasingly complex endeavour. With advancements in medical technology, the development and deployment of innovative devices have brought forth immense opportunities for improving patient care and revolutionizing the healthcare industry. At the same time, however, major markets such as Europe and the UK are experiencing unprecedented regulatory shake-ups in the form of the introduction of the new EU MDR and IVDR and the Future UK Regulatory System.

These regulations aim to safeguard patient safety, ensure device effectiveness, and maintain ethical standards throughout the product lifecycle, from design and manufacturing to post-market surveillance. However, achieving regulatory compliance in this intricate landscape is no simple task. It requires a deep understanding of the evolving regulatory landscape, meticulous planning, robust quality management systems, and effective risk assessment strategies.

“Manufacturers and stakeholders must navigate through a web of complex standards, guidelines, and country-specific regulations before they decide which markets will be the most profitable to enter and which ones they should tackle first, laying the groundworks for further expansion in the most time-efficient and cost-effective way possible. We felt the need to try and untangle some of this web for them, to ease their decision process and to hopefully shed some light on the different opportunities these areas have to offer.” comments Leeanne Baker, Managing Director and Quality & Regulatory Consultant.

This article was written by Medilink Midlands Member, IMed Consultancy. For more information on Medilink Midlands Membership, click here

Latest Opportunities

Outstanding lab facilities available for immediate lease

Charnwood Campus Labs and Offices Charnwood Campus Labs and Offices – Summerpool Rd, B28E, Loughborough,…

Exporting Starts Here programme for West Midlands companies

West Midlands Combined Authority (WMCA), funded by the UK Shared Prosperity Fund (UKSPF), has commissioned…

Tender brief – BlueSkeye AI Driver Fatigue evaluation

BlueSkeye AI is a software and AI business that provides innovative face and voice sensing…

Latest News

Mayor’s funding to harness video game technology for healthcare

World-leading gaming and immersive technology companies based in the West Midlands are being backed by…

Blüm Health Named Regional Winner at The Spectator Economic Innovator of the Year Awards 2025

Blüm Health is proud to announce that it has been awarded the Breakthrough – North…

Medilink Midlands Honors Departing Directors at AGM

Medilink Midlands formally acknowledges the outstanding service and leadership of three esteemed Directors, Keith Widdowson,…

Almost There! Just Tell Us a Bit About You​

Almost There! Just Tell Us a Bit About You​

Almost There! Just Tell Us a Bit About You​

Almost There! Just Tell Us a Bit About You​

Almost There! Just Tell Us a Bit About You​

Almost There! Just Tell Us a Bit About You​

Almost There! Just Tell Us a Bit About You​

Almost There! Just Tell Us a Bit About You​

Almost There! Just Tell Us a Bit About You​

Almost There! Just Tell Us a Bit About You​

Almost There! Just Tell Us a Bit About You​